Live Quote · OTCADYXHealthcare· Biotechnology

Adynxx, Inc.

$0.00 0.00%(+$0.00)
TickerSpark Score
65/100
Solid
80
Valuation
50
Profitability
80
Growth
84
Health
30
Momentum

Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ADYX research report →

52-Week Range0% of range
Low
$0.00
Current
$0.00
High
$0.00
Company Overviewwww.adynxx.com

About the company

Adynxx, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating and commercializing novel transcription factor decoy technologies to combat pain and inflammatory conditions. Central to its efforts is the AYX platform of transcription factor decoys, which includes brivoligide, currently progressing through Phase II clinical development for reducing post-surgical discomfort.

CEO
Richard Orr
IPO
1998
Employees
6
HQ
San Francisco, CA, US

Price Chart

+0.00% · this period
$0.00$0.00$0.00Jul 02Dec 31Jul 02
Valuation
Market Cap
$581
P/E
-0.00
P/S
0.00
P/B
0.00
EV/EBITDA
2.60
Div Yield
0.00%
Profitability
Gross Margin
22.38%
Op Margin
-238.99%
Net Margin
-379.83%
ROE
-70.38%
ROIC
-63.78%
Growth & Income
Revenue
$2.22M · 9.76%
Net Income
$-8,417,000 · 67.26%
EPS
$-10.26 · 71.45%
Op Income
$-5,296,000
FCF YoY
10.52%
Performance & Tape
52W High
$0.00
52W Low
$0.00
50D MA
$0.00
200D MA
$0.00
Beta
-8.54
Avg Volume
51

Get TickerSpark's AI analysis on ADYX

Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

Already have an account? Log in

Form 4 · Filings

Recent insider transactions

Who's buying, who's selling, and how much.

DateInsiderTypeShares
Jul 22, 19FLESHER GREGORY J.other0
May 29, 19GONZALEZ DINAother26,358
May 29, 19GONZALEZ DINAother1,577
May 29, 19GONZALEZ DINAother1,577
May 3, 19TPG Group Holdings (SBS) Advisors, Inc.other0
May 3, 19DP VIII Associates, L.P.other0
May 3, 19Domain Partners VIII, L.P.other0
May 3, 19ABEL STAN Eother54,117
May 3, 19ABEL STAN Eother27,940
May 3, 19ABEL STAN Eother198
Coverage · ADYX

Our ADYX coverage

Recent articles, reports, and earnings notes.

On-Demand Research

No research on ADYX yet

For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.

Generate ADYX report →
Internal Compare

Similar companies

Peers in the same neighborhood.